Natural Product HCV Drugs from Rare Plant-Microbe Interactions
Natural Product HCV Drugs from Rare Plant-Microbe Interactions
批准号:
8912993
负责人:
Mark T Hamann
金额:
$0.83万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-30 至 2016-03-31
关键词:
AddressAnabolismAngiospermsApplications GrantsBacteriaBiological AssayBiological FactorsBotanyChemical StructureCollaborationsCollectionCommunicable DiseasesCommunitiesCrude ExtractsDetectionDevelopmentDiseaseDrug resistanceEcologyEpigenetic ProcessFoundationsFractionationGenesGrantHabitatsHepatitis C virusHigh Pressure Liquid ChromatographyIn VitroInsectaLaboratoriesLinkLiver FailureMalignant NeoplasmsMedicineMethodologyMicrobeMississippiMolecularNaturePharmaceutical PreparationsPhylogenetic AnalysisPhylogenyPlant ExtractsPlant RootsPlantsProductionPublic HealthRecording of previous eventsRegulatory PathwayResistanceRoentgen RaysServicesSourceStaining methodStainsStructureTestingTimeTraditional MedicineUniversitiesdrug developmentdrug discoveryforestfungusinnovationinsightinterestmicrobial communitymicrobial hostmicrobiomenovelprogramsprototyperesistant strainsuccesstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The key objective of this project involves the exploration of US rare and endangered plants and their unique host-microbiome community. These communities will be studied for their biosynthesis and production of new classes of natural products (NPs) HCV drug leads with unique MOAs. The project involves a well established collaborative relationship with the laboratories of Prof Mark Hamann and at the University of Mississippi and Tony Whitaker with RFS Pharma and Raymond Schinazi at Emory University/Atlanta VA. The collective expertise provides a unique opportunity to explore new sources for treatments for HCV which are resistant to current forms of treatment. The specific aims of this program include: 1. A collection and phylogenetic analysis of 100 endangered plant associated bacteria and fungi strains each year. Phylogenetically diverse and unique US endangered plant species (20) will be evaluated for bacteria and fungi which inhibit HCV. This will provide 500 unique bacteria and fungi over the course of the five year project period. 2. Innovative epigenetic tools will be applied to stimulate production of secondary metabolites from silent genes. These will include regulatory tools available commercially as well as those derived from the host endangered plant itself. Each new strain will be subjected to 10 or more epigenetic tools. Highly sensitive HPLC with UV-TOF-ELS detection and small volume NMR will be utilized to evaluate NP production from genes silent under standard culture conditions. 3. A unique HCV real time PCR assay is featured in this grant application as a primary screen to identify extracts obtained from Aim 2 with HCV selectivity for fractionation in aim 4. 4. Active leads from Aim 3 will be purified using HPLC with MS, UV and ELSD detection. Repeated bioassays using real time PCR will be completed until HCV selective metabolites are generated. Natural product structures will be assigned using integrated NMR, HPLC-MS, UV, IR and X-ray crystallographic analysis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Synthesis and Optimization of the Aleutianamine Class of Alkaloids
-
批准号:10799135
-
项目类别:
-
资助金额:$16.57万
-
财政年份:2022
-
负责人:Mark T Hamann
-
依托单位:
Synthesis and Optimization of the Aleutianamine Class of Alkaloids
-
批准号:10345968
-
项目类别:
-
资助金额:$56.07万
-
财政年份:2022
-
负责人:Mark T Hamann
-
依托单位:
Support for Graduate, PDF and New Faculty Presenters at the 2022 American Society of Pharmacognosy Meeting
-
批准号:10469168
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2022
-
负责人:Mark T Hamann
-
依托单位:
Natural Product HCV Drugs from Rare Plant-Microbe Interactions
-
批准号:8707979
-
项目类别:
-
资助金额:$30.64万
-
财政年份:2012
-
负责人:Mark T Hamann
-
依托单位:
Natural Product HCV Drugs from Rare Plant-Microbe Interactions
-
批准号:8541704
-
项目类别:
-
资助金额:$30.64万
-
财政年份:2012
-
负责人:Mark T Hamann
-
依托单位:
Natural Product HCV Drugs from Rare Plant-Microbe Interactions
-
批准号:8339007
-
项目类别:
-
资助金额:$32.69万
-
财政年份:2012
-
负责人:Mark T Hamann
-
依托单位:
Natural Product HCV Drugs from Rare Plant-Microbe Interactions
-
批准号:9230277
-
项目类别:
-
资助金额:$29.81万
-
财政年份:2012
-
负责人:Mark T Hamann
-
依托单位:
Natural Product HCV Drugs from Rare Plant-Microbe Interactions
-
批准号:9127149
-
项目类别:
-
资助金额:$37.9万
-
财政年份:2012
-
负责人:Mark T Hamann
-
依托单位:
MARINE CYSTINE KNOT PEPTIDES
-
批准号:8361215
-
项目类别:
-
资助金额:$3.3万
-
财政年份:2011
-
负责人:Mark T Hamann
-
依托单位:
CHEMISTRY CORE
-
批准号:8167941
-
项目类别:
-
资助金额:$8.42万
-
财政年份:2010
-
负责人:Mark T Hamann
-
依托单位:
CHEMISTRY CORE
-
批准号:7959632
-
项目类别:
-
资助金额:$12.82万
-
财政年份:2009
-
负责人:Mark T Hamann
-
依托单位:
CHEMISTRY CORE
-
批准号:7720416
-
项目类别:
-
资助金额:$17.83万
-
财政年份:2008
-
负责人:Mark T Hamann
-
依托单位:
APPROACHES TO CHARACTERIZATION OF ANTIINFECTIVE AGENTS
-
批准号:2886084
-
项目类别:
-
资助金额:$6.74万
-
财政年份:1998
-
负责人:Mark T Hamann
-
依托单位:
APPROACHES TO CHARACTERIZATION OF ANTIINFECTIVE AGENTS
-
批准号:6532596
-
项目类别:
-
资助金额:$10.13万
-
财政年份:1998
-
负责人:Mark T Hamann
-
依托单位:
APPROACHES TO CHARACTERIZATION OF ANTIINFECTIVE AGENTS
-
批准号:6372593
-
项目类别:
-
资助金额:$9.47万
-
财政年份:1998
-
负责人:Mark T Hamann
-
依托单位:
APPROACHES TO CHARACTERIZATION OF ANTIINFECTIVE AGENTS
-
批准号:6168418
-
项目类别:
-
资助金额:$9.19万
-
财政年份:1998
-
负责人:Mark T Hamann
-
依托单位:
APPROACHES TO CHARACTERIZATION OF ANTIINFECTIVE AGENTS
-
批准号:2450444
-
项目类别:
-
资助金额:$6.74万
-
财政年份:1998
-
负责人:Mark T Hamann
-
依托单位:
ANTI AIDS AGENTS FROM MARINE ORGANISMS
-
批准号:2886946
-
项目类别:
-
资助金额:$13.46万
-
财政年份:1995
-
负责人:Mark T Hamann
-
依托单位:
ANTI AIDS AGENTS FROM MARINE ORGANISMS
-
批准号:2390408
-
项目类别:
-
资助金额:$12.6万
-
财政年份:1995
-
负责人:Mark T Hamann
-
依托单位:
ANTI AIDS AGENTS FROM MARINE ORGANISMS
-
批准号:2072951
-
项目类别:
-
资助金额:$10.63万
-
财政年份:1995
-
负责人:Mark T Hamann
-
依托单位:
海外基金